Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 398

1.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 29;31 Suppl 5:F1-31. doi: 10.1016/j.vaccine.2013.10.001. Review.

PMID:
24331745
2.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Nov 22;31 Suppl 8:I1-31. doi: 10.1016/j.vaccine.2013.07.026. Review.

3.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of ICO Monograph Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 31;31 Suppl 7:H1-31. doi: 10.1016/j.vaccine.2013.10.003.

PMID:
24332295
4.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 30;31 Suppl 6:G1-31. doi: 10.1016/j.vaccine.2013.10.002. Review.

PMID:
24331817
5.

Cancers attributable to human papillomavirus infection.

Grulich AE, Jin F, Conway EL, Stein AN, Hocking J.

Sex Health. 2010 Sep;7(3):244-52. doi: 10.1071/SH10020.

PMID:
20719211
6.

Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases.

Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane MA.

Vaccine. 2012 Nov 20;30 Suppl 5:F1-11. doi: 10.1016/j.vaccine.2012.05.090. Review.

PMID:
23199951
7.

Beyond cervical cancer: burden of other HPV-related cancers among men and women.

Chaturvedi AK.

J Adolesc Health. 2010 Apr;46(4 Suppl):S20-6. doi: 10.1016/j.jadohealth.2010.01.016.

PMID:
20307840
8.

Global burden of human papillomavirus and related diseases.

Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S.

Vaccine. 2012 Nov 20;30 Suppl 5:F12-23. doi: 10.1016/j.vaccine.2012.07.055. Review.

PMID:
23199955
9.

Burden of human papillomavirus infection and related diseases in Israel.

Shavit O, Roura E, Barchana M, Diaz M, Bornstein J.

Vaccine. 2013 Nov 22;31 Suppl 8:I32-41. doi: 10.1016/j.vaccine.2013.05.108. Review.

PMID:
24229717
10.

EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.

Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL, Denny L, Bornstein J, Abramowitz L, Giuliano A, Tommasino M, Monsonego J.

Int J Cancer. 2012 Nov 1;131(9):1969-82. doi: 10.1002/ijc.27650. Epub 2012 Jul 2. Review.

11.

Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.

Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjänen S, Poljak M.

Vaccine. 2013 Dec 31;31 Suppl 7:H46-58. doi: 10.1016/j.vaccine.2013.06.043.

PMID:
24332297
12.

Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.

Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, Yankey D, Edwards BK.

J Natl Cancer Inst. 2013 Feb 6;105(3):175-201. doi: 10.1093/jnci/djs491. Epub 2013 Jan 7.

13.

Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.

Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.

Vaccine. 2013 Aug 20;31(37):3922-7. doi: 10.1016/j.vaccine.2013.06.044. Epub 2013 Jun 24.

PMID:
23806241
14.

Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.

Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, Hortlund M, Liaw KL, Dasbach EJ, Kjær SK.

PLoS One. 2014 Feb 5;9(2):e88323. doi: 10.1371/journal.pone.0088323. eCollection 2014.

15.

Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.

Poljak M, Seme K, Maver PJ, Kocjan BJ, Cuschieri KS, Rogovskaya SI, Arbyn M, Syrjänen S.

Vaccine. 2013 Dec 31;31 Suppl 7:H59-70. doi: 10.1016/j.vaccine.2013.03.029. Review.

PMID:
24332298
16.

The HPV infection in males: an update.

Giraldi G, De Luca d'Alessandro E.

Ann Ig. 2012 Nov-Dec;24(6):497-506.

PMID:
23234187
17.

Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.

Toh ZQ, Licciardi PV, Fong J, Garland SM, Tabrizi SN, Russell FM, Mulholland EK.

Vaccine. 2015 Sep 22;33(39):5042-50. doi: 10.1016/j.vaccine.2015.07.102. Epub 2015 Aug 10. Review.

PMID:
26271829
18.

Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.

Poljak M.

Clin Microbiol Infect. 2012 Oct;18 Suppl 5:64-9. doi: 10.1111/j.1469-0691.2012.03946.x. Epub 2012 Aug 6. Review.

19.

The burden of human papillomavirus infections and related diseases in sub-saharan Africa.

De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, Denny L, Parham GP.

Vaccine. 2013 Dec 29;31 Suppl 5:F32-46. doi: 10.1016/j.vaccine.2012.07.092. Review.

20.

Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.

Serrano B, de Sanjosé S, Tous S, Quiros B, Muñoz N, Bosch X, Alemany L.

Eur J Cancer. 2015 Sep;51(13):1732-41. doi: 10.1016/j.ejca.2015.06.001. Epub 2015 Jun 26.

PMID:
26121913
Items per page

Supplemental Content

Write to the Help Desk